Jessica A. Pollard

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing et al. · Blood · 2009 · 216 citations · Full text

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

Jessica A. Pollard, Todd A. Alonzo, Robert B. Gerbing et al. · Blood · 2010 · 181 citations · Full text

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

Richard Aplenc, Soheil Meshinchi, Lillian Sung et al. · Haematologica · 2020 · 166 citations · Full text

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531

Jatinder K. Lamba, Lata Chauhan, Miyoung Shin et al. · Journal of Clinical Oncology · 2017 · 146 citations · Full text

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

Jessica A. Pollard, Michael R. Loken, Robert B. Gerbing et al. · Journal of Clinical Oncology · 2016 · 137 citations · Full text